Background: Cystic Fibrosis (CF) is one of the most common autosomal recessive genetic disorders, with the majority of patients born to couples unaware of their carrier status. Carrier screenings might help reducing the incidence of CF. Methods: We used a semi-automated reverse-dot blot assay identifying the 47 most common CFTR gene mutations followed by DGGE/dHPLC analysis. Results: Results of a 10-year (1996-2006) CF carrier screening on 57,999 individuals with no prior family history of CF are reported. Of these, 25,104 were couples and 7791 singles, with 77.9% from the Italian Veneto region. CFTR mutations were found in 1879 carriers (frequency 1/31), with ΔF508 being the most common (42.6%). Subjects undergoing medically assisted reproduction (MAR) had significantly (p b 0.0001) higher CF carrier frequency (1/22 vs 1/32) compared to non-MAR subjects. Conclusions: If coupled to counselling programmes, CF carrier screening tests might help reducing the CF incidence.
Introduction
Although newly developed therapies have increased life expectancy to late 30s, Cystic Fibrosis (CF) remains a serious and very often lethal disorder. The leading cause of morbidity and mortality is the progressive decline in pulmonary function [1] and approximately 85% of CF patients develop insufficiency of the exocrine pancreas. Nearly all CF males are infertile because of congenital bilateral absence of the vas deferens (CBAVD) [2, 3] . No definitive cures are available, even if experimental treatments based on gene therapy [4] and pharmacological approaches [5] aimed at modulating the residual activity of mutated Cystic Fibrosis Transmembrane conductance Regulator (CFTR) channels are currently being evaluated.
CF has a high incidence among the Caucasian population (1/2500) and more than 1500 different mutations have been identified. The risk of CF mutation carrier status varies by ethnicity, with the highest in people of Northern European ancestry (1/25) and of Ashkenazi Jewish descendent (1/29). As typical of recessive disorders, the majority of affected individuals are born to couples not knowing to be at risk. Heterozygotes are in fact phenotypically normal and most unaware of their carrier status. In 1989, CFTR gene cloning [6] opened up the possibility of identifying subjects at risk through DNA testing. Because of the high incidence of CFTR mutations, in 2001, the American College of Medical Genetics and the American College of Obstetricians and Gynecologists published guidelines [7, 8] for population-based CF screening and recommended CF carrier screening to be offered to couples in high-risk groups contemplating pregnancy. Screening tests are now offered by a number of genetic test providers and several testing platforms capable of automated, high-throughput and accurate identification of CFTR mutations have been developed.
Identification of novel (usually "mild") mutations and/or polymorphisms together with the development of sophisticated clinical tests have raised the issue of "atypical" or "nonclassical" forms of CF. Subjects with "atypical" CF may present with single organ involvement such as CBAVD, disseminated bronchiectasis, acute or chronic pancreatitis. The idea that "two mutations within the CFTR gene would mean CF and normal genes would exclude the diagnosis" has therefore not worked out that simply. The presence of mild mutations, polymorphisms and modifying genes is therefore widening the range of clinical phenotypes that previously would have never been considered within the CF spectrum thus posing important dilemmas to clinicians [9] .
In this study we report the results of a 10-year CF-carrier screening program on 57,999 subjects with no prior family history of CF. To our knowledge this is the most comprehensive screening for CF carriers in the Italian population, thus providing large-scale data on the frequency of CFTR mutations and raising important issues related to current genetic counselling practises.
Materials and methods

Subjects
The report presents the data gained from 59,782 adults enrolled in the CF carrier-screening program carried out at the Paediatrics Department at the University of Padova over a 10-year period (from 1996 to 2006). As 1783 subjects had a family history of CF, only 57,999 individuals were considered for CF carrier frequency evaluation (28,026 males and 29,973 females, ranging from 20 to 50 years of age, with 50,208 of whom belonging to 25,104 couples and the remaining 7791 being singles). All subjects were in good health, showed no clinical evidence of CF and had no relatives with CF. Individuals screened were informed about our CF carrier screening programme by their GPs (approximately 30%), friends/relatives previously screened and, importantly, public awareness raised by the Paediatrics Department through conferences and leaflets. For all of them knowing the risk to conceive a child with CF was the main reason to undertake the screening test.
Within this population, separate data were gathered from a sub-group of subjects (n = 5196) undergoing medically assisted reproduction (MAR) and being advised to carry out a CFTR mutation screening test by gynaeconologists or centres for MAR. Subjects reporting CF familiarity (n = 8) were not included in this sub-group.
Before collection of blood specimens, subjects were asked to fill out an informed consent form (approved by the Local Ethic Committee of the Paediatrics Department) providing information about CF, carrier-screening tests and the risks associated when mutations are identified. The costs associated with the screening tests are reimbursed by the Veneto region, with a small fee ("ticket") being paid by the subjects analysed.
Selection of mutations to be analysed
The choice of mutations to include in the screening test was made on the basis of databases [10] [11] [12] reporting the frequency of CFTR mutations in northern and southern Italy. Briefly, in northern Italy, the 15 most common mutations allowed a projected allele detection of 87.1%, with an estimated rate of detection of two CFTR mutations of 75.9% [10] . In southern Italy, the 13 most common mutations gave values of 85.7% and 73.4%, respectively, for the two parameters above mentioned [11, 12] . Forty-seven different CFTR mutations/gene alterations were chosen and analysed: ΔF508, G85E, 541delC, D110H, R117H, 621 + 1G→T, 711 + 5G→A, R334W, R334Q, T338I, R347H, R347P, R352Q, S466X, ΔI507, E527G, 1717-1G→A, 1717-8G→A, G542X, S549N, S549R A→C, G551D, Q552X, R553X, D579G, 1874insT, E585X, 1898 + 3A→G, 2183AA→G, 2184delA, R709X, 2789 + 5G→A, 3132delTG, 3199del6, 3272-26A→G, L1077P, L1065P, R1066H, M1101K, D1152H, R1158X, R1162X, 3849 + 10KbC→T, G1244E, W1282X, N1303K and 4016insT.
CFTR mutation analysis
CFTR gene mutations were identified through a semiautomated procedure based on a single multiplex PCR amplification followed by allele-specific oligonucleotide reverse-dot blot (RDB) as previously described [13] . Briefly, oligonucleotide probes complementary to the CFTR mutations listed above and their corresponding normal alleles were bound to a filter membrane to which biotin-labelled PCR products amplified from the subjects' DNA were subsequently hybridized.
DNA was extracted from 200 μl of peripheral blood lymphocytes using a Biorobot Multiprobe ® II Packard (Perkin Elmer, Waltham, MA, USA) and a QIAamp ® 96 DNA Blood Biorobot Qiagen kit (Qiagen GmbH, Hilden, Germany). Each DNA sample underwent four multiplex PCR amplifications: multiplex (A) for amplification of exons 7, 10, 13 and 19; (B) for exons 5, 11, 12 and 20; (C) for exons 3, 4, 14b and 21; (D) for exons 9, 17a, 17b, 18 and intron 19. Sequences of primers used for CFTR exon/intron amplifications were previously described [14] . Amplification of 400 ng genomic DNA was carried out using a PCR reaction mixture (30 μl) containing the following: 6.7 mM MgCl 2 , 1X buffer [67 mM Tris-HCl, pH 8,8, 1.66 mM (NH 4 )SO 4 , 0.1% Tween-20], 1.5 U of Taq polymerase (Polymed), 5 μM Biotin-16-dUTP, 100 μM of each dNTP and primers (1-2 nM each). PCR amplifications were performed with an initial denaturation step at 95°C for 5 min, followed by 35 cycles of denaturation (30 s at 94°C), annealing (45 s at 62°C) and extension (45 s at 72°C), followed by a final extension step of 7 min at 72°C.
To avoid false-negative results, in couples with one of the two partners carrying a CFTR mutation, DNA from the "negative" subject was further analysed by scanning all 27 exons and their intronic boundaries through Denaturing Gradient Gel Electrophoresis (DGGE) (Bio-Rad, Hercules, CA, USA) and/or denaturing High Performance Liquid phase Cromatography (dHPLC) (Transgenomic, Omaha, NE, USA) ( Fig. 1 ). Methods and procedures for DGGE and dHPLC were reported previously [15, 16] . Abnormal DGGE and/or dHPLC patterns were followed by automated DNA sequencing using an ABI PRISM 3100 sequencer (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Data are presented as counts and percentages. Odds-ratio and 95% confidence interval was used to estimate the risk of CF mutations of MAR subjects compared to non MAR subjects and the p value is obtained with the chi-square test.
Results
CF carrier testing in the general adult population
During the decade 1996-2006, a total of 59,782 subjects were assessed for their CF carrier status. Subjects having a family history of CF (n = 1783) were excluded from the study, thus restricting the number of individuals to be considered for CF carrier frequency evaluation to 57,999. Among all the individuals screened, we identified 1879 CF carriers with an overall frequency in the general population of 1:31 (3.23%). When individuals with a family history of CF were included (541 CF carriers were identified out of 1783 analysed), the frequency of carriers increased from 1:31 to 1:25. Since 77.9% of the subjects analysed were from the Veneto region and only subjects with no previous history of CF were included in this study, the 1:31 frequency value could be regarded as the potential a priori risk for CF carrier status for Italian northeastern populations. Distribution of CF mutation frequencies is indicated in Table 1 . As expected, ΔF508 was the most common mutation (42.6%).
In addition, 10 compound heterozygotes were identified and mutations are indicated in Table 2a . Interestingly 7 out of 10 subjects, despite not showing classical symptoms of CF, were found to have infertility problems, with 5 of them having CBAVD. For many of these subjects mutations were identified following DGGE and/or dHPLC analysis, and not through the RDB-based test, as gene alterations are "rare"/uncommon [A238V, R352W, S42F, (V201M, D1270N & R74W) and L206W] or because they have never been identified before [D372E (1251T→G) and L1414S (4373T→C)]. Our findings confirm what previously shown by other studies with regard to mild CFTR mutations/polymorphisms being associated with male infertility. For example, the compound heterozygote ΔF508/R117H, previously reported to occur commonly in CBAVD and infertile patients [20, 21] , was also a frequent genotype in our study (Table 2b ).
Frequency of CFTR mutations in couples from the general population
A total of 25,104 couples with no family history of CF contacted our centre in order to have a CFTR mutation screening carried out. Fig. 1 shows the flow of analyses undertaken by every couple entering our screening test, with 1st-(47 mutationbased RDB assay) and 2nd-level (dHPLC and/or DGGE) analyses. For 24,181 of these couples, results from RDB were negative and any further investigation terminated. In couples with one of the two partners carrying a mutation (identified Fig. 1 . Algorithm for CF carrier screening test. The strategy used in our study involves assays for multiple CFTR mutation detection (47 mutation based-RDB assay) and a "failsafe" protocol to discriminate potential false negatives. In couples with one of the two partners carrying a CFTR mutation, the "negative" subject is further analysed through DGGE and/or dHPLC. through RDB assay), the "negative" subject was further analysed through DGGE and/or dHPLC in order to discriminate potential false negatives. Overall, out of all the couples screened (n = 25,104), 815 had one of the two partners carrying a CFTR mutation and in 108 both partners were CF carriers, thus giving a 1/232 frequency of couples with both partners being heterozygotes in the general population. Couples with both partners identified as CF carriers have higher probabilities of pregnancies at risk and are therefore offered genetic counselling and prenatal diagnosis, if a pregnancy is ongoing. Of the 108 couples with both partners being identified as CF carriers, 89 had a pregnancy ongoing and prenatal CF screening test was carried out: 20 foetuses (22%) carried no mutations, 47 (53%) carried a mutation in one of the two CFTR alleles and 22 (25%) carried mutations on both alleles. Mutations found in the homozygous (n = 2) and heterozygous (n = 20) diagnosed foetuses are the following: ΔF508/ΔF508 (n = 1), 711 + 5G→A/711 + 5G→A (n = 1), ΔF508/P5L (n = 1), 2183AA→G/S42F (n = 1), ΔF508/ D1445N (n = 1), 711 + 5G→A/ΔF508 (n = 1), G542X/E527G (n = 1), N1303K/1717-1 G→A (n = 1), R117H/E527G (n = 1), ΔF508/2183AA→G (n = 1), ΔF508/D1152H (n = 1), R347H/ ΔF508 (n = 1), ΔF508/G542X (n = 2), ΔF508/N1303K (n = 2), R1162X/ΔF508 (n = 3), N1303K/D1152H (n = 3). Further information with regard to parents' decision following the results of the prenatal screening is not available.
CF carrier testing in couples entering medically assisted reproduction programs
The increasing use of assisted reproduction techniques to treat infertility has raised concerns about the risk of transmitting defective genes. For this reason, molecular screening to detect CFTR mutations is routinely performed before carrying out assisted reproduction fertilization procedures in couples with the male partner affected by CBAVD.
We, therefore, evaluated whether the frequency of CFTR mutations in a sub-group of individuals undergoing MAR (5196 subjects out of the 57,999 screened) was any different from percentages found in those not needing MAR. A total of 5196 subjects were screened for the presence of CFTR mutations and frequencies compared to those found in subjects (n = 52,803) not needing MAR. We identified 236 CF carriers within the Table 1 Frequency (%) of CF mutations in carriers from the general adult population (n = 1879) and from the population (n = 236) enrolled for medically assisted reproduction (MAR).
CF mutation
General (B) D372E (1251T→G) and L1414S (4373T→C) are CFTR mutation that have never been described before (see Table 4 ).
(C) Compound heterozygote subjects from population enrolled for medical assisted reproduction.
MAR subjects, giving an overall carrier frequency of 1/22 (4.25%), a value significantly higher (OR = 1.48, 95% CI from 1.29 to 1.70, p b 0.001) compared to that observed in individuals not needing MAR (1/32, n = 1643). The distribution of mutations in the identified carriers is shown in Table 1 . Among the subjects tested, 9 resulted to be compound heterozygotes: ΔF508/R117H (n = 3), G542X/D1152H (n = 1), R1162X/2789 + 5G→A (n = 1), R117H/2789 + 5G→A (n = 1), N1303K/D110H ( n = 1), N1303K/D1152H (n = 1), 2789 + 5G→A/R1066H (n = 1) ( Table 2b ). The identification of 3 subjects with ΔF508/ R117H confirmed findings from other studies reporting high frequencies of ΔF508/R117H compound heterozygotes in males with infertility problems [20, 21] .
"Rare" mutations having high frequencies and identification of new mutations
With the start of population screening tests, mutations commonly refereed as "rare" and not routinely screened for have been frequently identified, thus raising the issue of their involvement as disease-causing mutations. In our study, some of these mutations were found to have particularly high frequencies (Table 3) . These mutations were previously reported (see references in Table 3 ), but their effects on CFTR chloride channel activity not fully understood. Differently from previous reports, point mutation I148T was never found in close association with 3199del6 and similarly 3601-111 G→C with 1811+1,2KB A→G. In addition, DGGE-and/or dHPLC-mediated analysis of uncertain subjects coupled to DNA sequencing allowed the identification of 24 new mutations/polymorphisms, which have never been described before (Table 4 ).
Discussion
After the publication of the guidelines for CF carrier screening tests in the USA [7, 8] , Italian CF centres also started carrying out screening tests for CFTR mutations and providing newborn screening tests. The underlying hypothesis was that identification of the causative mutations in the affected child would allow the parents' mutations to be identified and their families to benefit by "cascade" family testing. However, newborn screening tests are unlikely to result in reduced CF incidence, being the primary aim to diagnose CF at early stages for the benefit of the affected child. Reduction in CF incidence could instead be achieved through CF carrier screening tests.
During the last 10 years (1996-2006), we have therefore screened 57,999 subjects with no history of CF. The aim was to establish the a priori risk for CF carrier status in the population analysed and to offer a reliable screening test to couples who wanted to plan a pregnancy and know their risk to conceive a CF child. With 1879 CF carriers identified out of 57,999 subjects with no previous history of CF, we estimated an overall CF carrier frequency of 1:31 (= a priori risk for Italian northeastern populations).
Setting up a CF carrier screening has raised important issues. Firstly, since the risk of carrying CF mutations varies by ethnicity and because of the large number of CFTR mutations, currently available screening tests have limitations. With a limited panel of CFTR mutations, many tests are insufficiently sensitive particularly in ethnically diverse populations. Recently, a diagnostic assay based on array primer extension technology was shown to detect up to 204 different CFTR mutations [28] . Our test based on a combination of RDB assay comprising 47 different mutations and DGGE/dHPLC has demonstrated to be a robust and easily modifiable screening test for CF carrier status evaluation as well as molecular diagnosis of affected individuals. Detection rate will surely increase following the inclusion of new mutations.
A second major issue with CF carrier tests is the identification of two apparent disease-causing mutations in individuals not previously diagnosed with CF. The combination of RDB and DGGE/dHPLC certainly increased the identification of CF carriers having "rare"/new mutations or polymorphisms. These are not normally considered disease-causing alterations, but when associated with more severe mutations, they could lead to CFTR-related disorders known as "atypical" or "nonclassical" forms of CF. Recently, a study of 335,204 patients screened for their CF carrier status revealed 4 individuals with Table 4 New CFTR mutations found in the general population following 2nd level analysis. Nucleotide change   A349V  1178C→T  D372E  1251T→G  D674V  2153A→T  D806G  2549A→G  I586V  1888A→G  I807V  2551A→G  I840T  2651T→C  L1335F  4135C→T  L1414S  4373T→C  L1480P  4571T→C  M348T  1175T→C  N416S  1379A→G  P1290T  4000C→T  P355S  1195C→T  Q1268R  3935A→G  Q1352E  4186C→G  S431G  2423A→G  S660T  2110T→A  S911R  2865T→G  T1263A  3919A→G  T788I  2495C→T  V920L  2890G→T  Y1381H  4273T→C  Y84H  382T→C two CFTR mutations and who had not been previously diagnosed with CF [29] . A likely explanation is that while severe genetic changes in the 2 CFTR alleles lead to severe forms of classical CF, other so-called mild mutations can cause milder or incomplete CFTR-associated phenotypes. While many of the 1500 different CFTR mutations are known to cause CF, the status of many missense mutations (around 40% of all mutations) is extremely difficult to assess, thus raising the issue of their involvement as disease causing mutations. In addition, a growing number of complex alleles are thought to affect the severity of the disease by modulating the effect of a mutation. The most striking example is the length of the intron 8 polythydimine tract on exon 9 splicing as genetic modifier of the severity of the R117H mutation. Interestingly, many missense mutations have been observed at frequencies higher than expected. In North America, for example, missense mutations I148T and D1270N were found N 100 and N200 times, respectively, more frequently in CF carriers than in patients. Whether these are real mutations or polymorphisms is debated, thus emphasizing the need for accurate screening in order to avoid the presence of second "severe" CFTR gene alterations. In our study a rare mutation such as S1235R was found to be moderately frequent (1/77) and despite being normally classified as "mild", association with a second CFTR gene mutation (G542X) can lead to idiopathic chronic pancreatitis [23] . Similarly, I148T was shown to be associated with a CF phenotype only when associated with mutation 3199del6 on the same gene [19] . The identification of mild or "rare" mutations determining variable, or unknown, phenotypes does therefore represent a serious dilemma for genetic counselling providers, especially in prenatal cases and in couples planning a pregnancy when both partners carry "rare"/mild CFTR mutations. With the development of more sophisticated screening tests, there will be increasing issues associated with the management of individuals carrying new polymorphisms and/or "not-disease-causing" mutations. A clear benefit of CF carrier screening tests is the possibility to evaluate potential links between CFTR mutations and malfunctioning male reproductive tracts. As reported by others, we also found a significantly higher frequency of CF carriers (1:22 vs 1:32) in subjects enrolled in MAR programmes. The link between CF and infertility is well documented [30] . Bilateral vessel agenesis is present in nearly 97% of CF males. CBAVD is also present in 1-2% of the infertile, but otherwise healthy, male population and accounts for more than 6% of cases of obstructive azoospermia. Approximately 75-80% of patients with CBAVD carry mutations in at least one CF allele. Homozygous CBAVD individuals show one severe and one mild pathogenic mutation or two mild mutations, but never two severe mutations. In addition to classic CFTR mutations, up to 40% of CBAVD patients show the 5T allele (5 thymidines within intron 8), known to reduce CFTR gene splicing efficiency. In our general population with no history of CF, 11 individuals were found to be compound heterozygote, with 3 having CBAVD and 5 general infertility problems. CBAVD patients have therefore a chance of 0.5 of transmitting the CFcausing CFTR mutation to the child (when MAR techniques are used). Assuming a risk of 1/25 of the partner of being a CF carrier, and when a carrier, again a chance of 0.5 of transmitting the mutant CFTR gene to the child, the combined risk of CBAVD couples of having a CF child is 1 in 100 (compared with a risk of 1/2500 in the control population). Genetic counselling should therefore be provided to couples with the male partner having CBAVD and both partners should be tested for CFTR mutations in order to determine the risk of having a CF child.
Aminoacid change
Finally, CF screening tests must have a significant uptake in the population to lead to a potential reduction in CF incidence. A measure of the success of our study was the constant increase of individuals being screened, starting with 1877 (3.2%) in 1996 up to 7453 (12.8% of the total) in 2002. A similar trend was observed in the sub-group comprising subjects with fertility problems, as individuals tested raised from 1 (0.1%) in 1996 up to 1096 (14.7%) in 2002. From 2002 to 2006, the numbers of test carried out diminished, likely because of others offering similar tests.
In conclusion, many benefits could be gathered from the set up of CF carrier screening tests and our findings could also serve as initial research tools for other CFTR-related diseases.
